Literature DB >> 29975112

Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.

Robin Fackrell1, Camille B Carroll2, Donald G Grosset3, Biju Mohamed4, Prashanth Reddy5, Miriam Parry5, Kallol Ray Chaudhuri6, Tom Foltynie7.   

Abstract

In the past 4 years, two adjunctive treatment options to levodopa have been licensed for use in the UK in patients with Parkinson's disease (PD) and motor fluctuations: opicapone, a third-generation catechol-O-methyl transferase inhibitor, and safinamide, a monoamine oxidase B inhibitor. This clinical consensus outlines the practical considerations relating to motor fluctuations and managing wearing-off in patients with PD, and provides a clinical insight to adjunctive treatment options, including opicapone and safinamide. Practice-based opinion was provided from a multidisciplinary steering Group of eight UK-based movement disorder and PD specialists, including neurologists, geriatricians and a nurse specialist, from England, Scotland and Wales.

Entities:  

Keywords:  Parkinson's disease; opicapone; safinamide

Mesh：

Substances：

Year:  2018        PMID： 29975112     DOI： 10.2217/nmt-2018-0020

Source DB:  PubMed          Journal:  Neurodegener Dis Manag        ISSN： 1758-2024


  9 in total

1.  Opicapone: A Review in Parkinson's Disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2021-01-11       Impact factor: 5.749

2.  Opicapone Efficacy and Tolerability in Parkinson's Disease Patients Reporting Insufficient Benefit/Failure of Entacapone.

Authors:  Petr Vokurka; Andrew Barron; Sheetal Sumaria; Lindsey Stockford; Paul Jarman; Kailash Bhatia; Simon Farmer; Tabish Saifee; Tom Warner; Rimona Weil; Sonia Gandhi; Patricia Limousin; Prasad Korlipara; Tom Foltynie
Journal:  Mov Disord Clin Pract       Date:  2020-10-21

Review 3.  Clinical Utility of Opicapone in the Management of Parkinson's Disease: A Short Review on Emerging Data and Place in Therapy.

Authors:  Linda Azevedo Kauppila; Daniela Pimenta Silva; Joaquim J Ferreira
Journal:  Degener Neurol Neuromuscul Dis       Date:  2021-05-11

4.  Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study.

Authors:  Masahiro Nomoto; Atsushi Takeda; Katsuaki Iwai; Akihisa Nishimura; Nobutaka Hattori
Journal:  Clin Pharmacol Drug Dev       Date:  2020-05-27

5.  Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations.

Authors:  Atsushi Takeda; Ryosuke Takahashi; Yoshio Tsuboi; Masahiro Nomoto; Tetsuya Maeda; Akihisa Nishimura; Kazuo Yoshida; Nobutaka Hattori
Journal:  Mov Disord       Date:  2020-10-19       Impact factor: 10.338

Review 6.  Systematic Review on Parkinson's Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson's Symptoms.

Authors:  Palanisamy Sivanandy; Tan Choo Leey; Tan Chi Xiang; Tan Chi Ling; Sean Ang Wey Han; Samantha Lia Anak Semilan; Phoon Kok Hong
Journal:  Int J Environ Res Public Health       Date:  2021-12-30       Impact factor: 3.390

7.  Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping.

Authors:  Ana I Loureiro; Carlos Fernandes-Lopes; Maria João Bonifácio; Filipa Sousa; László E Kiss; Patricio Soares-da-Silva
Journal:  Pharmacol Res Perspect       Date:  2022-02

8.  Absorption, metabolism and excretion of opicapone in human healthy volunteers.

Authors:  Ana I Loureiro; Francisco Rocha; Ana T Santos; Nand Singh; Maria João Bonifácio; Rui Pinto; Laszlo E Kiss; Patrício Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2022-05-20       Impact factor: 3.716

9.  Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.

Authors:  Masahiro Nomoto; Atsushi Takeda; Katsuaki Iwai; Akihisa Nishimura; Nobutaka Hattori
Journal:  Clin Pharmacol Drug Dev       Date:  2020-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.